bioAffinity Technologies, Inc. (BIAF) Price & Analysis

Compare

101 Followers

BIAF Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.16 - $2.99

Previous CloseN/A

Volume17.91K

Average Volume (3M)12.85M

Market Cap

$7.50M

Enterprise Value$64.67M

Total Cash (Recent Filing)$444.71K

Total Debt (Recent Filing)$1.33M

Price to Earnings (P/E)―

Beta-2.17

Next Earnings

Aug 19, 2025

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.16

Shares Outstanding28,459,541

10 Day Avg. Volume21,334,979

30 Day Avg. Volume12,845,352

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)-15.17

Price to Sales (P/S)0.00

P/FCF Ratio-24.48

Enterprise Value/Market Cap8.62

Enterprise Value/Revenue1.86

Enterprise Value/Gross Profit21.33

Enterprise Value/Ebitda-1.95

Forecast

1Y Price Target

$6.00

Price Target Upside2207.69% Upside

Rating ConsensusHold

Number of Analyst Covering1

bioAffinity Technologies, Inc. News

PremiumThe Fly

BioAffinity Technologies gets China patent for siRNA-based cancer therapy

9d ago

BIAF

PremiumCompany Announcements

bioAffinity Receives Nasdaq Non-Compliance Notice

1M ago

BIAF

PremiumThe Fly

BioAffinity gets U.S. patent for novel broad spectrum cancer therapies

1M ago

BIAF

PremiumCompany Announcements

bioAffinity Technologies Enters Sales Agreement with WallachBeth

1M ago

BIAF

PremiumThe Fly

BioAffinity Technologies appoints Dr. Gordon Downie as Chief Medical Officer

1M ago

BIAF

PremiumCompany Announcements

bioAffinity Technologies Sets 2025 Annual Meeting Date

1M ago

BIAF

PremiumCompany Announcements

bioAffinity Technologies Reports Strong Q1 2025 Growth

2M ago

BIAF

PremiumCompany Announcements

bioAffinity Technologies Completes $3.2M Public Offering

2M ago

BIAF

See All BIAF News

See All News >

Bulls Say, Bears Say

Bulls Say

Market AdoptionThe number of physician offices offering the CyPath Lung test increased significantly, indicating growing adoption of the diagnostic test.

Product ExpansionThe initial success of CyPath Lung in Texas has expanded to several other states through referrals and word-of-mouth, with expected momentum to continue through 2025.

Sales GrowthCyPath Lung sales were up 276% year-over-year, indicating strong growth potential despite some temporary setbacks.

Bears Say

Capital ConstraintsThe company's capital constraints remain a concern, impacting the ability to operate profitably without raising additional funds.

Revenue GuidanceThe company introduced 2025 revenue guidance significantly below prior estimates, leading to a downgrade of the stock to Hold.

Shareholder ImpactThe company needs to raise additional capital immediately, which could lead to share dilution for current shareholders.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

15.47% Insiders

0.93% Mutual Funds

0.32% Other Institutional Investors

83.13% Public Companies and Individual Investors

Detailed Ownership Overview >

BIAF FAQ

What was bioAffinity Technologies, Inc.’s price range in the past 12 months?

bioAffinity Technologies, Inc. lowest stock price was $0.16 and its highest was $2.99 in the past 12 months.

What is bioAffinity Technologies, Inc.’s market cap?

bioAffinity Technologies, Inc.’s market cap is $7.50M.

When is bioAffinity Technologies, Inc.’s upcoming earnings report date?

bioAffinity Technologies, Inc.’s upcoming earnings report date is Aug 19, 2025 which is in 47 days.

How were bioAffinity Technologies, Inc.’s earnings last quarter?

bioAffinity Technologies, Inc. released its earnings results on May 15, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.16.

Is bioAffinity Technologies, Inc. overvalued?

According to Wall Street analysts bioAffinity Technologies, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does bioAffinity Technologies, Inc. pay dividends?

bioAffinity Technologies, Inc. does not currently pay dividends.

What is bioAffinity Technologies, Inc.’s EPS estimate?

bioAffinity Technologies, Inc.’s EPS estimate is -0.1.

How many shares outstanding does bioAffinity Technologies, Inc. have?

bioAffinity Technologies, Inc. has 28,459,541 shares outstanding.

What happened to bioAffinity Technologies, Inc.’s price movement after its last earnings report?

bioAffinity Technologies, Inc. reported an EPS of -$0.16 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of bioAffinity Technologies, Inc.?

Currently, no hedge funds are holding shares in BIAF

Company Description

bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

BIAF Stock 12 Month Forecast

Average Price Target

$6.00

▲(2207.69%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Aug<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.48,0.9046153846153846,1.3292307692307692,1.7538461538461536,2.178461538461538,2.6030769230769226,3.0276923076923072,3.452307692307692,3.8769230769230765,4.3015384615384615,4.726153846153846,5.15076923076923,5.575384615384614,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.48,0.9046153846153846,1.3292307692307692,1.7538461538461536,2.178461538461538,2.6030769230769226,3.0276923076923072,3.452307692307692,3.8769230769230765,4.3015384615384615,4.726153846153846,5.15076923076923,5.575384615384614,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.48,0.9046153846153846,1.3292307692307692,1.7538461538461536,2.178461538461538,2.6030769230769226,3.0276923076923072,3.452307692307692,3.8769230769230765,4.3015384615384615,4.726153846153846,5.15076923076923,5.575384615384614,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.69,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.69,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.54,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.1,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.09,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.45,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.4,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.22,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.22,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.38,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >